Rankings
▼
Calendar
APLS Q4 2025 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
APLS
Apellis Pharmaceuticals, Inc.
$3B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$200M
-5.9% YoY
Gross Profit
$170M
85.1% margin
Operating Income
-$51M
-25.6% margin
Net Income
-$59M
-29.5% margin
EPS (Diluted)
$-0.47
QoQ Revenue Growth
-56.4%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$14M
Stock-Based Comp.
-$83M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$705M
Stockholders' Equity
$370M
Cash & Equivalents
$468M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$200M
$213M
-5.9%
Gross Profit
$170M
$172M
-0.9%
Operating Income
-$51M
-$26M
-95.5%
Net Income
-$59M
-$36M
-62.2%
Revenue Segments
Product
$190M
95%
Licensing And Other Revenue
$10M
5%
← FY 2025
All Quarters